Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sacoto

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Handbook of Experimental Pharmacology|December 15, 2021
Precision Medicine and ObesityDaniel Sacoto, Maria Daniela Hurtado, Andres Acosta
JAMA Network Open|September 19, 2022
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityWissam Ghusn, Alan De la Rosa, Daniel Sacoto, et al.
Obesity Pillars|November 22, 2023
A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management centerAlan De la Rosa, Wissam Ghusn, Daniel Sacoto, et al.
Mayo Clinic Proceedings|December 22, 2022
Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway VariantsLizeth Cifuentes, Alejandro Campos, Daniel Sacoto, et al.
Diabetes, Obesity & Metabolism|March 12, 2024
The association between previous use of anti-obesity medication and semaglutide weight loss outcomesWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Gastro Hep Advances|February 6, 2023
Association Between Food Intake and Gastrointestinal Symptoms in Patients With ObesityWissam Ghusn, Lizeth Cifuentes, Alejandro Campos, et al.
Journal of Racial and Ethnic Health Disparities|May 16, 2023
The Impact of Language on Hospital Outcomes for COVID-19 Patients: A Study of Non-English Speaking Hispanic PatientsSusan Lopez, Joshua Longcoy, Elizabeth Avery, et al.
International Journal of Obesity (2005)|February 1, 2024
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered studyWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Obesity (Silver Spring, Md.)|January 21, 2026
Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical TrialAlejandro Campos, Wissam Ghusn, Lizeth Cifuentes, et al.
Eclinicalmedicine|April 3, 2023
Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept studyLizeth Cifuentes, Wissam Ghusn, Fauzi Feris, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Handbook of Experimental Pharmacology|December 15, 2021
Precision Medicine and ObesityDaniel Sacoto, Maria Daniela Hurtado, Andres Acosta
JAMA Network Open|September 19, 2022
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityWissam Ghusn, Alan De la Rosa, Daniel Sacoto, et al.
Obesity Pillars|November 22, 2023
A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management centerAlan De la Rosa, Wissam Ghusn, Daniel Sacoto, et al.
Mayo Clinic Proceedings|December 22, 2022
Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway VariantsLizeth Cifuentes, Alejandro Campos, Daniel Sacoto, et al.
Diabetes, Obesity & Metabolism|March 12, 2024
The association between previous use of anti-obesity medication and semaglutide weight loss outcomesWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Gastro Hep Advances|February 6, 2023
Association Between Food Intake and Gastrointestinal Symptoms in Patients With ObesityWissam Ghusn, Lizeth Cifuentes, Alejandro Campos, et al.
Journal of Racial and Ethnic Health Disparities|May 16, 2023
The Impact of Language on Hospital Outcomes for COVID-19 Patients: A Study of Non-English Speaking Hispanic PatientsSusan Lopez, Joshua Longcoy, Elizabeth Avery, et al.
International Journal of Obesity (2005)|February 1, 2024
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered studyWissam Ghusn, Sima Fansa, Diego Anazco, et al.
Obesity (Silver Spring, Md.)|January 21, 2026
Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical TrialAlejandro Campos, Wissam Ghusn, Lizeth Cifuentes, et al.
Eclinicalmedicine|April 3, 2023
Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept studyLizeth Cifuentes, Wissam Ghusn, Fauzi Feris, et al.
Pageof 1